



18196-Review

Quotes Excluded
Bibliography Excluded13%
SIMILARName of journal: *World Journal of Hepatology*

ESPS Manuscript NO: 18196

Columns: MINIREVIEWS

18
Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk

Emanuel Raschi, Fabrizio De Ponti

Abstract

47
Drug- and Herb-Induced Liver Injury (DILI and HILI, respectively) is a hot topic for clinicians, academia, drug companies and regulators, as shown by the steadily increasing number of publications in the past 15 years. This review will first provide clues for clinicians to suspect idiosyncratic (unpredictable) DILI and succeed in diagnosis. Causality assessment remains challenging and requires careful medical history as well as awareness of multifaceted aspects, especially for herbs. Drug discontinuation and therapy

Match Overview

- | Rank | Source | Words | Similarity |
|------|---|-----------|------------|
| 1 | CrossCheck | 121 words | 1% |
| | Regev, Arie. "Drug-Induced Liver Injury and Drug Development: Industry Perspective", <i>Seminars in Liver Disease</i> , 20 | | |
| 2 | CrossCheck | 112 words | 1% |
| | Raschi, Emanuel, Elisabetta Poluzzi, Ariola Koci, Francesco Salvo, Antoine Pariente, Maurizio Biselli, Ugo Moretti, Nic | | |
| 3 | Internet | 100 words | 1% |
| | crawled on 12-Jan-2015
gi.org | | |
| 4 | CrossCheck | 93 words | 1% |
| | Björnsson, Einar. "Epidemiology and Risk Factors for Idiosyncratic Drug-Induced Liver Injury", <i>Seminars in Liver Disease</i> | | |
| 5 | Internet | 62 words | 1% |
| | crawled on 06-Apr-2014
www.hepatoweb.com | | |
| 6 | CrossCheck | 52 words | 1% |
| | Hayashi, Paul, and Robert Fontana. "Clinical Features, Diagnosis, and Natural History of Drug-Induced Liver Injury", <i>S</i> | | |



Drug- and Herb-Induced Liver Injury: progress, current challenges and e



网页

新闻

图片

视频

更多 ▾

搜索工具

找到约 65,600 条结果 (用时 0.69 秒)

Assessing liver injury associated with antimycotics: Concise ...

www.ncbi.nlm.nih.gov > ... > Literature > PubMed Central (PMC) - 翻译此页

作者: E Raschi - 2014 - 被引用次数: 2 - 相关文章

2014年8月27日 - Keywords: Drug-induced hepatotoxicity, Antimycotics, Drug safety, Pharmacovigilance, ... ketoconazole for drug-induced liver injury (DILI) poses a prescribing challenge to ..., to predict post-marketing risk of serious hepatic events and for making track emerging signals of DILI for newly marketed drug[42].

Recognizing Drug-Induced Liver Injury: Current Problems ...

tpx.sagepub.com/content/33/1/155.full ▾ 翻译此页

作者: WM Lee - 2005 - 被引用次数: 148 - 相关文章

Drug-induced liver injury (DILI) has become the leading cause for acute liver failure in ... Because risks associated with the new drug are unknown, caution has dictated that ... more serious signals but still do not represent true tests of liver function. The primary tool for study of adverse events occurring after marketing and ...

Additional Research Areas > Drug-Induced Liver Injury: A ...

www.fda.gov/Drugs/ScienceResearch/.../ucm091365.htm ▾ 翻译此页

Pre-Clinical Issues in Drug Development; Clinical Picture and Issues in the ... Current Topics in Hepatology ... Their metabolites may injure the liver cells, and complex drug-drug ... In January 2000 he moved to the Office of Postmarketing Drug Risk ... Refinement of these possible pre-marketing signals of injury is a major ...

[网页](#)[新闻](#)[图片](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 73,000 条结果 (用时 0.31 秒)

Google 学术: Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk

Clinical and causality assessment in herbal ... - Teschke - 被引用次数: 21

Assessing liver injury associated with antimycotics: Concise ...

www.ncbi.nlm.nih.gov > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者: E Raschi - 2014 - 被引用次数: 3 - 相关文章

2014年8月27日 - Keywords: Drug-induced hepatotoxicity, Antimycotics, Drug safety, Pharmacovigilance, ... ketoconazole for drug-induced liver injury (DILI) poses a prescribing challenge to to predict post-marketing risk of serious hepatic events and for making track emerging signals of DILI for newly marketed drug[42].

^[PDF] Drug-Induced Liver Injury: Premarketing Clinical Evaluation

www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf ▾ [翻译此页](#)

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It ... cause severe liver injury from signals that do not suggest such a potential. ... Hepatotoxicity discovered after approval for marketing drugs show this signal without conferring a risk of severe injury (e.g., tacrine, statins, ...

[网页](#)[新闻](#)[图片](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 90,600 条结果 (用时 0.90 秒)

Google 学术: Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk

Assessing liver injury associated with antimycotics: ... - Raschi - 被引用次数: 4

Clinical and causality assessment in herbal ... - Teschke - 被引用次数: 19

Assessing liver injury associated with antimycotics: Concise ...

www.ncbi.nlm.nih.gov > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者: E Raschi - 2014 - 被引用次数: 3 - [相关文章](#)

2014年8月27日 - Keywords: Drug-induced hepatotoxicity, Antimycotics, Drug safety, Pharmacovigilance, ... ketoconazole for drug-induced liver injury (DILI) poses a prescribing challenge to to predict post-marketing risk of serious hepatic events and for making track emerging signals of DILI for newly marketed drug[42].

^[PDF] Drug-Induced Liver Injury: Premarketing Clinical Evaluation

www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf ▾ [翻译此页](#)

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It ... cause severe liver injury from signals that do not suggest such a potential. ... Hepatotoxicity discovered after approval for marketing drugs show this signal without conferring a risk of severe injury (e.g., tacrine, statins,.